Showing 1 - 12 results of 12 for search 'Patrício Soares-da-Silva', query time: 0.06s Refine Results
  1. 1
    Comments on the Eslicarbazepine Acetate Section of the Article ‘Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications’

    Comments on the Eslicarbazepine Acetate Section of the Article ‘Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications’ by Patricio Soares-da-Silva, Ahmet H. Öztiryaki

    Published 2010-12-01
    Get full text
    Article
  2. 2
    Antagonistic modulation of SIK1 and SIK2 isoforms in high blood pressure and cardiac hypertrophy triggered by high-salt intake

    Antagonistic modulation of SIK1 and SIK2 isoforms in high blood pressure and cardiac hypertrophy triggered by high-salt intake by Nuno M. Pires, Bruno Igreja, Patrício Soares-da-Silva

    Published 2021-07-01
    Get full text
    Article
  3. 3
    Effects of nepicastat upon dopamine-β-hydroxylase activity and dopamine and norepinephrine levels in the rat left ventricle, kidney, and adrenal gland

    Effects of nepicastat upon dopamine-β-hydroxylase activity and dopamine and norepinephrine levels in the rat left ventricle, kidney, and adrenal gland by Diogo Nóbrega Catelas, Maria Paula Serrão, Patricio Soares-Da-Silva

    Published 2020-02-01
    Get full text
    Article
  4. 4
    Bioelectrical impedance analysis of body composition for the anesthetic induction dose of propofol in older patients

    Bioelectrical impedance analysis of body composition for the anesthetic induction dose of propofol in older patients by Ana M. Araújo, Humberto S. Machado, Amílcar C. Falcão, Patrício Soares-da-Silva

    Published 2019-10-01
    Get full text
    Article
  5. 5
    Correction to: Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study

    Correction to: Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study by Heinz Reichmann, Andrew Lees, José-Francisco Rocha, Diogo Magalhães, Patrício Soares-da-Silva, the OPTIPARK investigators

    Published 2020-04-01
    Get full text
    Article
  6. 6
    Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study

    Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study by Heinz Reichmann, Andrew Lees, José-Francisco Rocha, Diogo Magalhães, Patrício Soares-da-Silva, the OPTIPARK investigators

    Published 2020-03-01
    Get full text
    Article
  7. 7
    Metabolism and disposition of opicapone in the rat and metabolic enzymes phenotyping

    Metabolism and disposition of opicapone in the rat and metabolic enzymes phenotyping by Ana I. Loureiro, Carlos Fernandes‐Lopes, Maria João Bonifácio, Filipa Sousa, László E. Kiss, Patricio Soares‐da‐Silva

    Published 2022-02-01
    Get full text
    Article
  8. 8
    The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II

    The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II by José-Francisco Rocha, Georg Ebersbach, Andrew Lees, Eduardo Tolosa, Joaquim J. Ferreira, Werner Poewe, Olivier Rascol, Fabrizio Stocchi, Angelo Antonini, Diogo Magalhães, Helena Gama, Patrício Soares-da-Silva

    Published 2021-11-01
    Get full text
    Article
  9. 9
    The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II

    The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II by José-Francisco Rocha, Georg Ebersbach, Andrew Lees, Eduardo Tolosa, Joaquim J. Ferreira, Werner Poewe, Olivier Rascol, Fabrizio Stocchi, Angelo Antonini, Diogo Magalhães, Helena Gama, Patrício Soares-da-Silva

    Published 2022-08-01
    Get full text
    Article
  10. 10
    Opicapone versus placebo in the treatment of Parkinson’s disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial

    Opicapone versus placebo in the treatment of Parkinson’s disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind O... by K. Ray Chaudhuri, Per Odin, Joaquim J. Ferreira, Angelo Antonini, Olivier Rascol, Mónica M. Kurtis, Alexander Storch, Kirsty Bannister, Patrício Soares-da-Silva, Raquel Costa, Diogo Magalhães, José Francisco Rocha

    Published 2022-03-01
    Get full text
    Article
  11. 11
    Antiepileptogenesis after stroke—trials and tribulations: Methodological challenges and recruitment results of a Phase II study with eslicarbazepine acetate

    Antiepileptogenesis after stroke—trials and tribulations: Methodological challenges and recruitment results of a Phase II study with eslicarbazepine acetate by Matthias J. Koepp, Eugen Trinka, Yee‐Haur Mah, Carla Bentes, Susanne Knake, Gian Luigi Gigli, José M. Serratosa, Johan Zelano, Luís M. Magalhães, Ana Pereira, Joana Moreira, Patrício Soares‐da‐Silva

    Published 2023-09-01
    Get full text
    Article
  12. 12
    Lack of salt-inducible kinase 2 (SIK2) prevents the development of cardiac hypertrophy in response to chronic high-salt intake.

    Lack of salt-inducible kinase 2 (SIK2) prevents the development of cardiac hypertrophy in response to chronic high-salt intake. by Sergej Popov, Hiroshi Takemori, Takeshi Tokudome, Yuanjie Mao, Kentaro Otani, Naoki Mochizuki, Nuno Pires, Maria João Pinho, Anders Franco-Cereceda, Lucia Torielli, Mara Ferrandi, Anders Hamsten, Patricio Soares-da-Silva, Per Eriksson, Alejandro M Bertorello, Laura Brion

    Published 2014-01-01
    Get full text
    Article

Search Tools: